{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:45:50Z","timestamp":1783446350978,"version":"3.55.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Gilead Sciences Inc."}],"content-domain":{"domain":["journalofclinicalvirology.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.jcv.2018.03.012","type":"journal-article","created":{"date-parts":[[2018,4,2]],"date-time":"2018-04-02T14:47:49Z","timestamp":1522680469000},"page":"37-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Rare emergence of drug resistance in HIV-1 treatment-na\u00efve patients receiving elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide for 144 weeks"],"prefix":"10.1016","volume":"103","author":[{"given":"Nicolas","family":"Margot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moupali","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"McCallister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Callebaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2018.03.012_bib0005","series-title":"Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Developed by the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents \u2013 A Working Group of the Office of AIDS Research Advisory Council (OARAC)","author":"Department for Health and Human Services (DHHS)","year":"2015"},{"issue":"2","key":"10.1016\/j.jcv.2018.03.012_bib0010","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/QAI.0000000000001350","article-title":"Brief report: randomized, double-Blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E\/C\/F) for initial HIV-1 treatment: week 144 results","volume":"75","author":"Arribas","year":"2017","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jcv.2018.03.012_bib0015","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials","volume":"385","author":"Sax","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jcv.2018.03.012_bib0020","series-title":"Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment. Guidance for Industry","author":"U.S. Department of Health and Human Services","year":"2015"},{"key":"10.1016\/j.jcv.2018.03.012_bib0025","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1128\/AAC.44.4.920-928.2000","article-title":"A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1","volume":"44","author":"Petropoulos","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"10.1016\/j.jcv.2018.03.012_bib0030","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1089\/aid.2010.0123","article-title":"HIV-1 integrase sequence variability in antiretroviral naive patients and in triple-class experienced patients subsequently treated with raltegravir","volume":"26","author":"Varghese","year":"2010","journal-title":"AIDS Res. Hum. Retrovir."},{"issue":"3","key":"10.1016\/j.jcv.2018.03.012_bib0035","first-page":"642","article-title":"2014 update of the drug resistance mutations in HIV-1","volume":"22","author":"Wensing","year":"2014","journal-title":"Top. Antivir. Med."},{"issue":"3","key":"10.1016\/j.jcv.2018.03.012_bib0040","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1128\/AAC.44.3.568-573.2000","article-title":"A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184\u202fV","volume":"44","author":"Hertogs","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.jcv.2018.03.012_bib0045","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3851\/IMP1748","article-title":"Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy","volume":"16","author":"Young","year":"2011","journal-title":"Antivir. Ther."},{"issue":"2","key":"10.1016\/j.jcv.2018.03.012_bib0050","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3851\/IMP1749","article-title":"Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient","volume":"16","author":"Boyd","year":"2011","journal-title":"Antivir. Ther."},{"issue":"5","key":"10.1016\/j.jcv.2018.03.012_bib0055","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/2325957415596229","article-title":"Five antiretroviral drug class-resistant HIV-1 in a treatment-naive patient successfully suppressed with optimized antiretroviral drug selection","volume":"14","author":"Volpe","year":"2015","journal-title":"J. Int. Assoc. Provid. AIDS Care"},{"issue":"3","key":"10.1016\/j.jcv.2018.03.012_bib0060","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3851\/IMP2885","article-title":"Week 144 resistance analysis of elvitegravir\/cobicistat\/emtricitabine\/tenofovir DF versus efavirenz\/emtricitabine\/tenofovir DF in antiretroviral-naive patients","volume":"20","author":"White","year":"2015","journal-title":"Antivir. Ther."},{"issue":"5","key":"10.1016\/j.jcv.2018.03.012_bib0065","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1310\/hct1504-218","article-title":"Week 144 resistance analysis of elvitegravir\/cobicistat\/emtricitabine\/tenofovir DF versus atazanavir\u202f+\u202fritonavir\u202f+\u202femtricitabine\/tenofovir DF in antiretroviral-naive patients","volume":"15","author":"Kulkarni","year":"2014","journal-title":"HIV Clin. Trials"},{"issue":"5","key":"10.1016\/j.jcv.2018.03.012_bib0070","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1086\/381784","article-title":"Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients","volume":"189","author":"Miller","year":"2004","journal-title":"J. Infect. Dis."},{"issue":"9","key":"10.1016\/j.jcv.2018.03.012_bib0075","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/00002030-200206140-00004","article-title":"Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF","volume":"16","author":"Margot","year":"2002","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.jcv.2018.03.012_bib0080","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1086\/314560","article-title":"Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro","volume":"179","author":"Miller","year":"1999","journal-title":"J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.jcv.2018.03.012_bib0085","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/135965350100600205","article-title":"Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication","volume":"6","author":"Naeger","year":"2001","journal-title":"Antivir. Ther."},{"issue":"11","key":"10.1016\/j.jcv.2018.03.012_bib0090","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1128\/AAC.46.11.3437-3446.2002","article-title":"Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R\u202f+\u202fM184V and their effects on enzyme function and viral replication capacity","volume":"46","author":"White","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.jcv.2018.03.012_bib0095","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1074\/jbc.M308806200","article-title":"Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations","volume":"279","author":"Deval","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.jcv.2018.03.012_bib0100","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1128\/JVI.02712-06","article-title":"The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions","volume":"81","author":"Cong","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.jcv.2018.03.012_bib0105","series-title":"Paper Presented At: International Workshop on HIV Drug Resistance and Treatment Strategies","author":"Perez-Valero","year":"2017"},{"issue":"7","key":"10.1016\/j.jcv.2018.03.012_bib0110","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1468-1293.2006.00404.x","article-title":"Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in study 903","volume":"7","author":"Margot","year":"2006","journal-title":"HIV Med."},{"issue":"2","key":"10.1016\/j.jcv.2018.03.012_bib0115","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/QAI.0b013e3181b05f7c","article-title":"Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naive subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine\/zidovudine and efavirenz in study GS-01-934","volume":"52","author":"Margot","year":"2009","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"11","key":"10.1016\/j.jcv.2018.03.012_bib0120","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","article-title":"Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial","volume":"13","author":"Raffi","year":"2013","journal-title":"Lancet Infect. Dis."},{"issue":"5","key":"10.1016\/j.jcv.2018.03.012_bib0125","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/QAI.0000000000000790","article-title":"Brief report: dolutegravir plus abacavir\/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial","volume":"70","author":"Walmsley","year":"2015","journal-title":"J. Acquir. Immune Defic. Syndr."}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653218300891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653218300891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T20:22:51Z","timestamp":1660767771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653218300891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":25,"alternative-id":["S1386653218300891"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2018.03.012","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rare emergence of drug resistance in HIV-1 treatment-na\u00efve patients receiving elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide for 144 weeks","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2018.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}